摘要
目的:探讨D-二聚体对社区获得性肺炎病情及预后的评估价值。方法:选择某院收治的48例患者,在入院治疗前对D-二聚体进行检测,分析社区获得性肺炎(CAP)患者D-二聚体含量与CURB-65系统评分等级的差异;比较治疗后生存组和死亡组及不同CURB-65系统评分等级患者的D-二聚体含量变化,分析CAP患者的住院时间。结果:根据CURB-65系统评分结果,48例CAP患者中重症患者10例,非重症患者38例;非重症CAP患者D-二聚体浓度为(1558±617)ng/m L,重症CAP患者D-二聚体浓度为(2088±658)ng/m L,2者比较差异有统计学意义(P<0.05)。治疗后生存组D-二聚体浓度为(1610±658)ng/m L,死亡组(2例)D-二聚体浓度为(2765±567)ng/m L,2组比较差异有统计学意义(P<0.05);对不同评分等级的CAP患者住院时间分析结果显示,Score 2患者住院天数(12.7±4.52)d与Score 0患者(7.20±2.02)d及Score 1患者(7.92±2.51)d比较,差异有统计学意义(P<0.05)。结论:D-二聚体能够一定程度上反应CAP患者的病情及预后情况,但是在用于临床前需要进一步的研究和校正。
Objective：To research the evaluating value of D-dimer for condition and prognosis of patients with community acquired pneumonia （CAP）. Methods ：48 patients in a hospital were included as research subjects. The concentration of plasma D-dimer was measured before treatment, and the difference between the D-dimer concentration and CURB-65 system rating scale was analyzed. After treatment, the difference of the D-dimer concentration between the survival group and the death group was researched, and the hospitali- zation time of patients with CAP was also analyzed. Resuits：According to the results of CURB-65 rating system,there were 10 cases of patients with severe CAP and 38 cases with non-severe CAP in all patients. The D-dimer concentration was higher in those with severe CAP （ 2088 ng/mL ±658 ng/mL versus 1558 ng/mL ±617 ng/mL, P 〈 0.05 ）. After the treatment, the non-survivors had higher D-di- mer levels （2765 ng/mL ±567 ng/mL versus 1610 ng/mL ± 658 ng/mL, P 〈0. 05）. The hospitalization time of the patients with score 2 was longer than those with score 0 and score 1 （ P 〈 0.05 ）. Conclusion ： D-dimer can be used to reflect condition and prognosis of patients with CAP, but it needs further study and correction before it is used in clinical practice.
出处
《淮海医药》
CAS
2018年第2期141-143,146,共4页
Journal of Huaihai Medicine
